INTRODUCTION
============

Crohn's disease (CD) is a chronic and recurrent intestinal inflammatory disorder that typically affects young females of reproductive age \[[@b1-ir-2019-00103]-[@b7-ir-2019-00103]\]. Previous retrospective studies suggest that CD is associated with decreased fertility rate \[[@b8-ir-2019-00103]-[@b14-ir-2019-00103]\]. CD-associated inflammation in the pelvis, including the fallopian tubes and ovaries, as well as surgery-related chronic tubal adhesions, 1could potentially affect fertility of female CD patients \[[@b15-ir-2019-00103]-[@b19-ir-2019-00103]\]. In addition, voluntary childlessness due to excessive anxiety and lack of disease knowledge could also lead to a decreased fertility rate \[[@b20-ir-2019-00103]\].

Ovarian reserve, which reflects the quantity and quality of oocytes in the ovary, is an indicator of fertility in females of reproductive age \[[@b21-ir-2019-00103],[@b22-ir-2019-00103]\]. Conventional hormonal tests, including follicle-stimulating hormone (FSH), luteinizing hormone and estrogen, have been utilized to evaluate ovarian reserve. However, these methods are limited, as sample collection is required on a specific day of the menstrual cycle \[[@b23-ir-2019-00103]\]. Anti-Müllerian hormone (AMH), a new hormone marker of ovarian reserve, can be measured on any day of the menstrual cycle, as it remains stable throughout the cycle \[[@b24-ir-2019-00103],[@b25-ir-2019-00103]\]. As an early, reliable and quantitative indicator, AMH is considered the most accurate hormonal marker of ovarian reserve \[[@b26-ir-2019-00103]\].

To date, only limited data regarding serum AMH levels in female CD patients is available with inconsistent findings \[[@b27-ir-2019-00103]-[@b29-ir-2019-00103]\]. In the study reported by Şenateş et al. \[[@b28-ir-2019-00103]\], AMH was measured in a relatively small sample of 35 CD patients, and AMH levels in CD patients were significantly lower compared to the controls. However, in another study including 50 patients with CD \[[@b27-ir-2019-00103]\], no statistical difference was found between mean serum AMH levels in CD and control women. Moreover, risk factors associated with decreased ovarian reserve remain unclarified \[[@b27-ir-2019-00103],[@b29-ir-2019-00103]\]. This is an important knowledge gap that identifying risk factors associated with decreased ovarian reserve could help to prevent impairment of ovarian reserve. The aim of the current study was to both investigate AMH level alteration in female CD patients and identify independent risk factors affecting decreased AMH levels in a case-control study based on sample size calculation.

METHODS
=======

1. Study Design and Population
------------------------------

We performed an individually matched, case-control cross-sectional study at the First Affiliated Hospital of Sun Yat-Sen University, a tertiary IBD referral center, from January 2013 to March 2018. Reproductive age was defined as 18 to 45 years old \[[@b20-ir-2019-00103]\]. CD diagnosis was defined through clinical manifestations and endoscopic, radiologic, and histopathological findings \[[@b3-ir-2019-00103]\]. Exclusive criteria were: age less than 18 years old or more than 45 years old, oral contraceptive taking history, a gynecological and endocrine relevant surgical history, cytotoxic drugs history, pelvic radiotherapy history, diagnosed or potential polycystic ovary syndrome, thyroid disease, hyperprolactinemia or other relevant diseases, diagnosed or potential malignancies or other gynecological organic diseases \[[@b27-ir-2019-00103],[@b28-ir-2019-00103]\]. Healthy controls were recruited from local communities. Controls were matched with CD patients for age, height and weight in a 1:1 ratio, non-pregnancy and not taking oral contraceptive. We obtained informed consent from all cases and controls. The study protocol was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University (IRB No. 2015-47).

2. AMH Measurement
------------------

Ovarian reserve was determined by serum AMH levels measured by ELISA (AMH Gen II ELISA, Kangrun Biotech Co., Ltd., Guangzhou, China) in duplicate samples for the cases and controls as previously reported \[[@b24-ir-2019-00103]\]. Briefly, blood samples were collected from the cubital vein of all included subjects after a 12-hour fast. Blood samples were centrifuged at 2,000 g for 15 minutes at 4°C within 2 hours of venipuncture. All serum samples were immediately stored in polypropylene tubes at --80°C until further analysis. The range of detection was 0.05 to 15.93 ng/mL with intra- and inter-assay coefficients of variation below or equal to 4.71% and 5.87%. To minimize the chance of bias in the assay, all sera were processed on the same day, using the same measurement kits, and by the same operator.

3. Definitions
--------------

Low ovarian reserve was defined as serum AMH levels below 2 ng/mL \[[@b27-ir-2019-00103],[@b30-ir-2019-00103]\]. In an additional analysis, diminished ovarian reserve was also pragmatically defined as serum AMH levels below 1.1 ng/mL \[[@b31-ir-2019-00103]\]. CD activity was evaluated by the CDAI. Patients with a CDAI score less than 150 were considered to be in remission, and a CDAI score over 150 was considered active. The chronic diarrhea was defined as loose or watery stools \>25% of the time without predominant abdominal pain or bloating (criterion fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis and patients meeting criteria for diarrhea-predominant IBS should be excluded) \[[@b32-ir-2019-00103]\].

4. Sample Size Calculation
--------------------------

The sample size was determined based on a level of significance, two-sided test at α=0.05 and power (1-β) of 0.8 with sampling ratio of 1:1 \[[@b33-ir-2019-00103]\]. This calculation was based on an estimated number of possible cases with low AMH levels in the CD and control groups \[[@b27-ir-2019-00103]\]. These data were combined with several assumptions to determine that a sample size of 60 subjects in each group would have an 80% power to detect a difference in low AMH level events.

5. Statistical Analysis
-----------------------

All statistical data were analyzed with SPSS version 12.0 software (SPSS Inc., Chicago, IL, USA). An unpaired *t*-test and paired *t*-test were used for normally distributed data, and the Wilcoxon signed-rank test was used for non-normally distributed data. Dichotomized variables were compared using a chi-square test or Fisher two-tailed test. A logistic regression was constructed with the most informative variables. Only variables with *P*\<0.10 were retained in the final model using a forward stepwise approach. Adjusted OR and 95% CI were derived from the estimated regression coefficients. A two-tailed *P*-value \<0.05 was considered to be significant.

RESULTS
=======

1. Patient Demographic Characteristics
--------------------------------------

A total of 87 female CD patients and 87 healthy controls were included in the final analysis. The demographic and clinical characteristics are presented in [Table 1](#t1-ir-2019-00103){ref-type="table"}. The median CD duration was 6.1 years (range, 0.3--15.6 years). Forty-three CD patients were in an active disease state and 44 were in remission. Seven CD patients had not used any medical treatment. The remaining patients had received at least 1 month of medical treatment prior to blood sample collection, including 11 patients who received 5-aminosalicylic acid (5-ASA), 5 patients who received steroids, 39 patients who received azathioprine (AZA), 21 patients who received thalidomide, and 4 patients who received infliximab.

2. AMH levels in CD Patients and Healthy Controls
-------------------------------------------------

The comparison and distribution of serum AMH levels in CD patients and matched healthy controls are presented in [Fig. 1A](#f1-ir-2019-00103){ref-type="fig"}. The mean serum AMH level in CD patients (2.47±2.08 ng/mL) was significantly lower than that of the control group (3.87±1.96 ng/mL, *P*\<0.001). In the paired comparison, statistical difference was also found between CD patients and matched controls (*P*\<0.001) ([Fig. 1B](#f1-ir-2019-00103){ref-type="fig"}). When groups were divided based on age, serum AMH levels were comparable between CD patients and healthy controls for patients younger than 25 years old (4.41±1.52 ng/mL vs. 3.49±2.10 ng/mL, *P*=0.06), however, serum AMH levels were significantly lower in CD patients older than 25 years (*P*\<0.05 for all comparisons) ([Fig. 1C](#f1-ir-2019-00103){ref-type="fig"}).

3. Correlation between Clinical Characteristics and AMH Levels
--------------------------------------------------------------

The mean AMH level for the 43 CD patients in an active disease state was 1.34±1.39 ng/mL, a lower value than both the 44 patients in remission (3.52±2.09 ng/mL, *P*\<0.001) and the control group (3.87±1.96 ng/mL, *P*\<0.001) ([Fig. 2A](#f2-ir-2019-00103){ref-type="fig"}). CD patients in a mildly active disease state showed higher serum AMH levels than patients in a moderately/severe active disease state (1.64±1.45 ng/mL vs. 0.38±0.34 ng/mL, *P*=0.007) ([Fig. 2B](#f2-ir-2019-00103){ref-type="fig"}).

Although the serum level of AMH was significantly lower in patients with stricturing CD (B2; 1.22±1.25 ng/mL) compared with non-stricturing/penetrating CD (B1; 2.83±2.12 ng/mL, *P*=0.006) ([Fig. 2C](#f2-ir-2019-00103){ref-type="fig"}), no significant difference was found between patients with non-stricturing/penetrating (B1) and penetrating CD (B3) patients (2.24±2.29 ng/mL, *P*=0.418). CD patients with perianal disease (1.57±1.71 ng/mL) had lower serum AMH levels than patients without perianal disease (2.80±2.12 ng/mL, *P*=0.015) ([Fig. 2D](#f2-ir-2019-00103){ref-type="fig"}). When assessing disease location, we found that patients with ileocolonic CD (L3) were more likely to show lower serum AMH levels (2.02±1.94 ng/mL) than patients with ileal CD (L1; 2.73±2.08 ng/mL, *P*=0.192) or colonic involved CD (L2; 2.97±2.23 ng/mL, *P*=0.081). However, none of these comparisons were statistically different ([Fig. 2E](#f2-ir-2019-00103){ref-type="fig"}).

The AMH levels of CD patients receiving thalidomide therapy (0.89±0.93 ng/mL) were significantly lower than the AMH levels of patients treated with 5-ASA or no medication (3.08±1.85 ng/mL, *P*\<0.001), AZA (2.89±2.08 ng/mL, *P*\<0.001) or steroid/infliximab (3.12±2.79 ng/mL, *P*=0.005). However, there was no significant difference in AMH levels among patients receiving 5-ASA or no medication, AZA and steroid/infliximab treatment ([Fig. 2F](#f2-ir-2019-00103){ref-type="fig"}). In addition, compared with normal control group, the AMH levels of 5-ASA/no treatment CD patient presented no statistical difference (3.08±1.85 ng/mL vs. 3.87±1.96 ng/mL, *P*=0.652).

4. Risk Factors Associated with Low Ovarian Reserve
---------------------------------------------------

When a low ovarian reserve was defined as a serum AMH level less than 2 ng/mL, univariate analyses suggested that age greater than 25 (OR, 5.12; 95% CI, 1.82--14.42; *P*=0.002), duration more than 6 years (OR, 2.64; 95% CI, 1.10--6.34; *P*=0.029), stricturing disease (B2) (OR, 3.70; 95% CI, 1.15--12.09; *P*=0.028), perianal disease (OR, 3.34; 95% CI, 1.23--9.07; *P*=0.018), active disease state (OR, 13.65; 95% CI, 4.79--38.91; *P*\<0.001) and thalidomide use (OR, 8.50; 95% CI, 1.96--36.79; *P*=0.004) were associated with low ovarian reserve. Variables with *P*\<0.10 (age greater than 25 years, duration more than 6 years, stricturing disease, perianal disease, active disease state, thalidomide use, and IBD related surgery history) were included in a multivariable logistic regression analysis. We found that age greater than 25 years (OR, 10.03; 95% CI, 1.90--52.93; *P*=0.007), active disease state (OR, 27.99; 95% CI, 6.13--127.95; *P*\<0.001) and thalidomide use (OR, 15.66; 95% CI, 2.22--110.65; *P*=0.006) were independent risk factors for low ovarian reserve ([Table 2](#t2-ir-2019-00103){ref-type="table"}). On a secondary analysis of diminished ovarian reserve defined as AMH ≤1.1 ng/mL, age greater than 25 years, active disease state and thalidomide use were still independent risk factors ([Table 3](#t3-ir-2019-00103){ref-type="table"}).

DISCUSSION
==========

AMH is a member of the transforming growth factor-β (TGF-β) family and is produced by the granulose cells of preantral and small antral follicles \[[@b34-ir-2019-00103]\]. Together with antral follicle count, inhibin B and FSH concentration per cycle day, AMH levels have been used to measure ovarian reserve \[[@b25-ir-2019-00103]\]. AMH remains stable throughout the menstrual cycle, thus has been replacing traditional FSH, luteinizing hormone, and estrogen tests of ovarian status in assisted reproductive technologies-*in vitro* fertilization \[[@b24-ir-2019-00103]\] and malignancy chemotherapy \[[@b35-ir-2019-00103]\], as well as in rheumatic diseases such as systemic lupus erythematosus \[[@b36-ir-2019-00103]\] and Behçet's disease \[[@b37-ir-2019-00103]\]. AMH is currently considered the most accurate hormonal marker of ovarian reserve. The present study suggests that AMH levels are decreased in female CD patients over 25 years old, whereas serum AMH levels remained equivalent to controls in young women less than 25 years old. In contrast, Fréour et al. \[[@b27-ir-2019-00103]\] reported that AMH levels remained comparable between CD and control women over 30 years old, but levels were significantly lower in CD women under 30 years old. This difference in findings may be ascribed to the fact that only young women with CD in remission were included in the Fréour et al. \[[@b27-ir-2019-00103]\], while both active and remission patients were included in the current study.

Inflammatory burden related to CD plays an important role in fertility alterations, even without structural lesions in the gynecological system \[[@b28-ir-2019-00103]\]. In a study with small sample size of 35 female patients, Şenateş et al. \[[@b28-ir-2019-00103]\] reported a negative correlation between CDAI and serum AMH levels. Similarly, our study found that serum AMH levels were significantly lower in patients in an active disease state than for those in remission. Moreover, CD patients in a mildly active disease state showed higher serum AMH levels than patients in a moderately or severely active disease state. This finding may indicate that serum AMH levels are inversely correlated with the severity of CD activity.

Colonic location of CD has been reported to be independently associated with a high risk of altered ovarian reserve \[[@b27-ir-2019-00103]\]. However, through a multivariate analysis, our data suggest that disease location is not associated with a lower ovarian reserve. Although stricturing behavior and perianal disease are risk factors associated with poor outcome of CD \[[@b38-ir-2019-00103]-[@b40-ir-2019-00103]\], neither of these factors were correlated with lower ovarian reserve in our study, a finding that is inconsistent with previous studies \[[@b27-ir-2019-00103]\]. These data may imply that disease location and behavior may not have a direct impact on ovarian reserve, while disease activity might have direct impact on ovarian reserve.

Another novelty of the present study was a design that allowed us to investigate the potential impact of medication use on ovarian reserve. Indeed, whether medications, including steroid and immunosuppressive agents, can influence fertility outcomes is of great concern to both patients and doctors. Our results suggest that steroids, 5-ASA, thiopurines and infliximab have no significantly different effect on serum AMH levels compared with CD patients who had no medication or 5-ASA in reproductive age. However, thalidomide therapy was associated with lower ovarian reserve, which was in line with a previous study \[[@b29-ir-2019-00103]\]. These findings imply that ovarian reserve should be monitored in female CD patients of reproductive age who are using thalidomide. Thalidomide is an immunomodulatory drug used in some patients with CD refractory to first- or second-line therapy. Previous studies report that the overall prevalence of amenorrhea was 0.02% in patients using thalidomide \[[@b41-ir-2019-00103]\]. The immunosuppressive effects of thalidomide may also suppress functions of TGF-α, TGF-β, or interleukin-1β, which are important for the growth and development of primordium follicles and oocytes \[[@b42-ir-2019-00103]-[@b45-ir-2019-00103]\]. Nevertheless, the exact mechanism of thalidomide effects on ovarian reserve, as well as possible ovarian reserve impairment reversals, remains to be clarified in future prospective studies.

Our study has certain limitations. First, limited data are currently available on reference values of AMH. We used 2 ng/mL, the value of 25th percentile in a healthy population with regular cycling. This value has been used previously as the diagnostic standard of low ovarian reserve \[[@b27-ir-2019-00103]\]. We also performed an additional analysis by defining diminished ovarian reserve as serum AMH levels below 1.1 ng/mL, and similar results were found. Second, the influence of AMH levels on actual fertility outcomes was not reported in this cross-sectional study. Long-term prospective studies are needed to define the relationship between AMH levels and fertility results. Moreover, the impact of medication use on AMH level was analyzed by logistic analysis, and the numbers of included patients had some differences. There were only 4 patients received infliximab treatment, while 21 patients received thalidomide treatment in our study. Future studies with more cases, especially using infliximab are needed. In addition, the proportion of patients receiving thalidomide in our study seems to be relatively high. Due to medical reimbursement policy in China, a large number of refractory CD patients who cannot afford biologics such as infliximab, and thalidomide is a good option for them in such circumstance \[[@b46-ir-2019-00103]-[@b48-ir-2019-00103]\]. More patients with different types of therapies will be included in future studies based on a great change in reimbursement policy recently, such as infliximab using, in China. Finally, a comparison of AMH levels before and after medical treatment is needed in a longitudinal study with more patients using biologics.

This study focused on the ovarian reserve and explored influencing factors of CD patients in reproductive age, which would guide patient's fertility in further clinical practice. In addition, our study also suggested that AMH assessment could be recommended for female CD patients who had fertility needs.

In conclusion, our study suggests that ovarian reserve is impaired in female CD patients compared to healthy controls. Age over 25 years old, active disease state and thalidomide use were independently associated with low ovarian reserve.
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###### 

Baseline Demographic and Clinical Characteristics of the Patients and Healthy Controls

  Characteristic                  CD patient (n=87)   Control (n=87)   *P*-value
  ------------------------------- ------------------- ---------------- -----------
  Age (yr)                        30 (18--45)         30 (18--45)      0.933
  Age distribution (yr)                                                
   18--25                         31 (36)             31 (36)          1.000
   26--30                         20 (23)             20 (23)          1.000
   31--35                         16 (18)             16 (18)          1.000
   36--40                         10 (11)             10 (11)          1.000
   41--45                         10 (11)             10 (11)          1.000
  Height (cm)                     159.5 ± 3.5         160.7 ± 3.6      0.423
  Weight (kg)                     50.9 ± 6.4          54.8 ± 6.8       0.335
  BMI (kg/m^2^)                   20.4 ± 2.3          21.4 ± 2.8       0.062
  Participants with children      46 (53)             56 (64)          0.915
  Participants with miscarriage   5 (6)               4 (5)            0.732
  Family history of GI diseases                                        
   Inflammatory disease           3 (3)               0                0.081
   GI tumor                       7 (8)               8 (9)            0.787
   Chronic diarrhea               3 (3)               2 (2)            0.650

Values are presented as median (range), number (%), or mean±SD.

###### 

Univariate and Multivariable Analysis of Factors Associated with Low Ovarian Reserve (AMH ≤2 ng/mL) in CD Female Patients

  Characteristic                                                               AMH   Univariable analysis   Multivariable analysis                                     
  ---------------------------------------------------------------------------- ----- ---------------------- ------------------------ ---------- ---------------------- ----------
  Age (yr)                                                                                                                                                             
   ≤ 25                                                                        6     24                     Reference                                                  
   \> 25                                                                       32    25                     5.12 (1.82--14.42)       0.002      10.03 (1.90--52.93)    0.007
  Duration (yr)                                                                                                                                                        
   ≤ 6                                                                         15    26                     Reference                                                  
   \> 6                                                                        23    23                     2.64 (1.10--6.32)        0.029                             
  IBD related surgery history^[a](#tfn1-ir-2019-00103){ref-type="table-fn"}^                                                                                           
   Yes                                                                         8     5                      2.35 (0.70--7.87)        0.167                             
   No                                                                          30    44                     Reference                                                  
  Disease behavior                                                                                                                                                     
   B1                                                                          23    39                     Reference                                                  
   B2                                                                          11    5                      3.70 (1.15--12.09)       0.028                             
   B3                                                                          4     5                      1.36 (0.33--5.57)        0.672                             
  Perianal disease                                                                                                                                                     
   Yes                                                                         15    8                      3.34 (1.23--9.07)        0.018                             
   No                                                                          23    41                     Reference                                                  
  Disease activity                                                                                                                                                     
   In remission                                                                7     37                     Reference                                                  
   Active disease                                                              31    12                     13.65 (4.79--38.91)      \< 0.001   27.99 (6.13--127.95)   \< 0.001
  Location                                                                                                                                                             
   L1                                                                          9     15                     Reference                                                  
   L2                                                                          7     16                     0.73 (0.22--2.45)        0.610                             
   L3                                                                          22    18                     2.04 (0.74--5.73)        0.178                             
  Upper GI location^[b](#tfn2-ir-2019-00103){ref-type="table-fn"}^                                                                                                     
   Yes                                                                         7     4                      2.54 (0.69--9.42)        0.163                             
   No                                                                          31    45                     Reference                                                  
  Medication history                                                                                                                                                   
   5-ASA/no treatment                                                          6     12                     Reference                                                  
   Steroid/infliximab                                                          3     6                      1.00 (0.18--5.46)        0.999                             
   AZA                                                                         12    27                     0.89 (0.27--2.93)        0.847                             
   Thalidomide                                                                 17    4                      8.50 (1.96--36.79)       0.004      15.66 (2.22--110.65)   0.006

Defined as any surgery that comprised of a diversion, stricturoplasty, and luminal resection, anytime during the follow-up period. Perianal abscess drainage or seton placement were not included.

Includes all patients with upper GI tract disease associated with intestinal disease, instead of isolated upper GI disease.

AMH, anti-Müllerian hormone; B, behavior; L, location; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine.

###### 

Univariate and Multivariable Analysis of Factors Associated with Low Ovarian Reserve (AMH≤1.1 ng/mL) in CD Female Patients

  Characteristic                                                               AMH   Univariable analysis   Multivariable analysis                                     
  ---------------------------------------------------------------------------- ----- ---------------------- ------------------------ ---------- ---------------------- ----------
  Age (yr)                                                                                                                                                             
   ≤ 25                                                                        4     26                     Reference                                                  
   \> 25                                                                       26    31                     5.45 (1.68--17.65)       0.005      15.28 (2.08--112.08)   0.007
  Duration (yr)                                                                                                                                                        
   ≤ 6                                                                         13    33                     Reference                                                  
   \> 6                                                                        17    24                     1.79 (0.73--4.39)        0.198                             
  IBD related surgery history^[a](#tfn3-ir-2019-00103){ref-type="table-fn"}^                                                                                           
   Yes                                                                         8     5                      3.38 (1.11--12.86)       0.033                             
   No                                                                          22    52                     Reference                                                  
  Disease behavior                                                                                                                                                     
   B1                                                                          17    45                     Reference                                                  
   B2                                                                          9     7                      3.40 (1.10--10.58)       0.034                             
   B3                                                                          4     5                      2.12 (0.58--8.83)        0.303                             
  Perianal disease                                                                                                                                                     
   Yes                                                                         12    11                     2.79 (1.04--7.45)        0.041                             
   No                                                                          18    46                     Reference                                                  
  Disease activity                                                                                                                                                     
   In remission                                                                5     39                     Reference                                                  
   Active disease                                                              25    18                     10.83 (3.57--32.90)      \< 0.001   36.27 (4.69--147.23)   \< 0.001
  Location                                                                                                                                                             
   L1                                                                          7     17                     Reference                                                  
   L2                                                                          6     17                     0.86 (0.23--3.09)        0.814                             
   L3                                                                          17    23                     1.79 (0.61--5.29)        0.289                             
  Upper GI location^[b](#tfn4-ir-2019-00103){ref-type="table-fn"}^                                                                                                     
   Yes                                                                         6     5                      2.60 (0.72--9.37)        0.144                             
   No                                                                          24    52                     Reference                                                  
  Medication history                                                                                                                                                   
   5-ASA/no treatment                                                          3     15                     Reference                                                  
   Steroid/infliximab                                                          2     7                      1.43 (0.19--10.58)       0.727                             
   AZA                                                                         10    29                     1.72 (0.41--7.23)        0.456                             
   Thalidomide                                                                 15    6                      12.50 (2.63--59.47)      0.002      38.18 (4.18--348.14)   0.001

Defined as any surgery that comprised of a diversion, stricturoplasty, and luminal resection, anytime during the follow-up period. Perianal abscess drainage or seton placement were not included.

Includes all patients with upper GI tract disease associated with intestinal disease, instead of isolated upper GI disease.

AMH, anti-Müllerian hormone; B, behavior; L, location; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine.

[^1]: These authors contributed equally to this study.
